Fagron posts 6.4% revenue growth in Q3, reaffirms full-year outlook
BRUSSELS: Fagron, a global leader in pharmaceutical compounding, reported a 6.4% increase in third-quarter revenue, reaching €228.2 million, and reaffirmed its full-year guidance amid continued momentum across regions and business lines. Organic growth at constant exchange rates (CER) rose 10.3%, or 8.5% on a normalized basis, with 5.7% growth including the impact of GLP-1-related dynamics….